Navigation Links
MDS Nordion Provides Update to Medical Isotope Customers
Date:11/30/2007

OTTAWA, Nov. 30 /PRNewswire-FirstCall/ - MDS Nordion, a leading provider of medical isotopes and radiopharmaceuticals, has provided an update to their medical isotope customers about a temporary supply issue. MDS Nordion has received information from their primary supplier regarding an interruption in the supply of molybdenum-99 used in the manufacturing of technetium-99m generators and iodine-131. The primary supplier has advised MDS Nordion that a scheduled reactor maintenance shutdown has been extended to complete an upgrade to the electrical system, addressing a technical regulatory issue.

MDS Nordion's primary supplier is working closely with their regulator, the Canadian Nuclear Safety Commission, to finalize and complete implementation of their upgrade plan. At the same time, MDS Nordion is working closely with their global supply network to mitigate the impact of this temporary supply issue on their customers. Based on our current information, an approval of the upgrade plan is anticipated shortly with a targeted return to full production in mid-December. The impact of this interruption is currently expected to reduce EBITDA by up to approximately US $4 million in the first quarter of 2008.

About MDS Nordion

MDS Nordion (http://www.mdsnordion.com) is a world leader in medical isotopes, radiation and related technologies. It is a business unit of MDS Inc. (TSX:MDS)(NYSE:MDZ). MDS Inc. is a global life sciences company that provides market-leading products and services for the development of drugs and diagnosis and treatment of disease. We are a leading global provider of pharmaceutical contract research, medical isotopes for molecular imaging, radiotherapeutics, and analytical instruments. MDS Inc. has more than 6,200 highly skilled people in 28 countries. Find out more at http://www.mdsinc.com or by calling 1-888-MDS-7222, 24 hours a day.

Forward-Looking Statement

This document contains forward-looking statements. Some forward-looking statements may be identified by words like "expects", "anticipates", "plans", "intends", "indicates", "targeted" or similar expressions. The statements are not a guarantee of future impact or performance and are inherently subject to risks and uncertainties. The actual impact to the Company of the maintenance shutdown could differ materially from that currently anticipated due to a number of factors, including, the actual timing of a return to full production and other risk factors identified in other documents filed by the Company with Canadian and US securities regulatory authorities from time to time.


'/>"/>
SOURCE MDS Nordion
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. MDS Nordion signs 17-year contract with Rosenergoatom
2. MDS Nordion Divests Non Strategic Product Lines
3. Study provides hope that some transplant patients could live free of antirejection drugs
4. Study provides hope that some transplant patients could live free of anti-rejection drugs
5. USAID Provides Additional Wildfire Assistance to Greece
6. Proven Nutrition Provides Energy and Hope to Cancer Fighters
7. LifeMasters Provides Tips for Maintaining a Healthy Blood Cholesterol Level
8. New knock-out gene model provides molecular clues to breast cancer
9. PreMD Provides Update on 510(k) Application for PREVU(x) POC
10. SIV infection of natural hosts provides new insights into HIV disease complexity
11. Microarray provides 3 genomic guides to breast cancer treatment decisions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... A recent ... that most people are unfamiliar with. The article goes on to state that individuals ... also many of these less common operations such as calf and cheek reduction. The ...
(Date:6/24/2016)... ... 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. ... the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has ... , Sickle Cell Disease (SCD) is a disorder of the red blood cells, which ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Dr. Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile ... orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can ...
(Date:6/24/2016)... ... , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business ... to $12 an hour by 2020 and then adjusting it yearly to increase at the ... minimum wage, assure the wage floor does not erode again, and make future increases more ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Tenn. , June 24, 2016  Arkis ... providing less invasive and more durable cerebrospinal fluid ... in funding.  The Series-A funding is led by ... Lighthouse Fund, and other private investors.  Arkis, new ... neurosurgical instrumentation and the market release of its ...
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
Breaking Medicine Technology: